drug development
The DECODE Obesity working group aims to evaluate physical activity, function and sleep in a remote patient environment.
This collaboration will work with an unnamed pharma company in Japan to know how its drugs behave compared to rival products.
The funds will be used for product development and building customer-facing teams.
The keynote presenter at HIMSS’ Accelerate Health event shares his game plan for how stakeholders can use big data to improve the quality, safety and effectiveness of drug therapies.
The yet-to-be-named programme reportedly “leverages machine learning to optimise a clinical trial’s chances of success” through the analysis of factors such as patient population recruitment and dropout rate.
It works to more easily connect patients to trials, decrease administrative tasks, improve trial resiliency and enhance studies through the use of data and technology.
The company's drug development CRO, Covance, will integrate Medable's software to expand its decentralized trial capabilities.
Bayer and Exscientia will initially work on three early-stage projects using AI to speed up drug discovery.
From streamlining operations to fine-tuning optimal treatments, the technology makes a business case for pharma.
In July, MobiHealthNews will focus on how pharma companies are using digital tools for R&D, real-world evidence collection and exploring new therapeutics.